28 results on '"Atadja, P."'
Search Results
2. Stroke-Induced Respiratory Dysfunction Is Associated With Cognitive Decline.
3. FXR1 regulates transcription and is required for growth of human cancer cells with TP53/FXR2 homozygous deletion
4. Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED.
5. Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction.
6. Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of a Novel Histone Deacetylase Inhibitor, LAQ824, in Human Colon Carcinoma Cells and Xenografts
7. Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia
8. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
9. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair
10. ING1 and 5-azacytidine act synergistically to block breast cancer cell growth.
11. Involvement of histone acetylation of Sox17 and Foxa2 promoters during mouse definitive endoderm differentiation revealed by microRNA profiling.
12. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.
13. Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo
14. Polycomb target genes are silenced in multiple myeloma.
15. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
16. PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance
17. Analysis of pan-African Centres of excellence in health innovation highlights opportunities and challenges for local innovation and financing in the continent
18. Discovery of Potent and Selective Allosteric Inhibitors of Protein Arginine Methyltransferase 3 (PRMT3).
19. Absolute Quantification of Histone PTM Marks by MRM-Based LC-MS/MS.
20. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
21. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells.
22. Conformational Refinement of Hydroxamate-Based Histone Deacetylase Inhibitors and Exploration of 3-Piperidin-3-ylindole Analogues of Dacinostat (LAQ824).
23. Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia.
24. 151 POSTER Efficacy of panobinostat (LBH589) in lung cancer: potent anticancer activity in both in vitro and in vivo tumor models.
25. 702 POSTER Phase I pharmacokinetic and pharmacodynamic study of once-weekly IV LBH589.
26. 161 POSTER Potent anticancer activity of panobinostat (LBH589) in models of hormone-refractory prostate cancer (HRPC): targeting the androgen receptor.
27. 701 POSTER Phase I study of oral LBH589 in advanced solid tumours and non-Hodgkin's lymphoma.
28. 584 POSTER Histone deacetylase inhibitors abrogate the levels and activity of estrogen receptor (ER) α and histone deacetylase (HDAC) 6 in human breast cancer cells (BCCs).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.